Capdevila, JaumeGomez, Ma AuxiliadoraGuillot, MonicaPaez, DavidPericay, CarlesSafont, Maria JoseTarazona, NoeliaVera, RuthVidal, JoanaSastre, Javier2023-05-032023-05-032022-02-22Capdevila J, Gómez MA, Guillot M, Páez D, Pericay C, Safont MJ, et al. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021). Clin Transl Oncol. 2022 Apr;24(4):646-657. doi: 10.1007/s12094-022-02816-9. Epub 2022 Mar 18. Erratum in: Clin Transl Oncol. 2022 Jul;24(7):1443-1444http://hdl.handle.net/10668/21130The management of localized rectal cancer requires a multidisciplinary approach to optimize outcomes, reduce morbidity and prevent under or overtreatments. While early stages may obtain benefit of local resections without any additional therapies, locally advanced rectal cancer becomes a challenge defining the better sequential strategy of surgery, radiotherapy and chemotherapy. The latest results of international phase III studies have positioned the total neoadjuvant therapy as a potential new standard of care in high risk rectal cancers, however, the best schedule is still not well defined.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/GuidelineRectal cancerTotal neoadjuvant therapyAntineoplastic combined chemotherapy protocolsChemoradiotherapyHumansNeoadjuvant therapyNeoplasm stagingNeoplasms, second primaryRectal neoplasmsRectumresearch article35303269open accessEstadificación de neoplasiasNeoplasias primarias secundariasNeoplasias del rectoProtocolos de quimioterapia combinada antineoplásicaQuimioradioterapiaRectoTerapia neoadyuvante10.1007/s12094-022-02816-91699-3055PMC8986677https://link.springer.com/content/pdf/10.1007/s12094-022-02816-9.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986677/pdf